Compare Twist Bioscience Corp (TWST) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Upstart Holdings Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Upstart Holdings Inc trades at $26.01 (market cap $2.63B). The key difference: Twist Bioscience Corp is far larger — about 3.2× Upstart Holdings Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| TWST | UPST | |
|---|---|---|
Market Cap | $8.42B | $2.63B |
Sector | Health | Financials |
52-Week High | $153.10 | $68.11 |
52-Week Low | $24.16 | $24.22 |
Enterprise Value | $8.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting recent bearish momentum amid mixed earnings performance. The stock shows oversold technical signals with an RSI of 18.98, while fundamentals highlight a return to profitability in 2025 with net income of $53.60M on $1.02B revenue. Recent news indicates strategic refocus on personal loans and AI-driven lending growth, though cash flow volatility and high debt levels pose concerns. Analyst consensus remains divided with a $45.00 price target suggesting significant upside potential from current levels.
The outlook for UPST hinges on execution in AI-powered lending expansion and margin improvement, with risks including consumer credit stress and competitive pressures. Institutional sentiment is cautiously optimistic, but investors should monitor debt management and quarterly earnings consistency for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
